A New Face of Fibrin-Associated Large B-Cell Lymphoma: Epstein–Barr Virus-Positive Breast Implant-Associated Diffuse Large B-Cell Lymphoma

Abstract

Recently, there have been reports of what could be a new lymphoproliferative entity: breast implant-associated Epstein–Barr virus positive (EBV+) diffuse large B-cell lymphoma (EBV+ BIA-DLBCL). The new World Health Organization classification has categorized it as fibrin-associated large B-cell lymphomas (FA-LBCLs); therefore, it could be referred to as breast implant-associated fibrin-associated large B-cell lymphomas (BIA-FA-LBCLs). Although the association between breast implants and lymphomas has been known since the mid-1990s, it has been almost exclusively breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Here, we describe the first case of BIA-FA-LBCL at our center, with a literature review of the clinical features, diagnosis and treatment approach of this lymphoma. We also explore the differential diagnosis of BIA-FA-LBCL, highlighting the diagnostic challenges and the reasons that have led these lymphomas to being labeled as a new face of FA-LBCL.

Severe capsular contracture in a patient with a history of multiple malignancies – Hematoma or neoplasm recurrence?: A case report

“…The potential complications include hematoma, seroma, infection, capsular contracture, implant rupture, and prosthesis-related malignancies, such as breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), breast implant-associated squamous cell carcinoma (BIA-SCC), and breast implant-associated diffuse large B-cell lymphoma (BIA-DLBCL). [ 2 – 5 ] The occurrence of these complications is not uncommon, as evidenced by relevant literature indicating that the hematoma incidence in postmastectomy implant-based breast reconstruction ranges from 4% to 9%. [ 6 ] However, the incidence rate of capsular contracture varies significantly across different sources due to factors such as radiotherapy, prosthesis placement level, and types of prostheses used.…”